Clinical Trial Update: Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 trial comparing SU011248 to standard chemotherapy in patients with previously treated triple-negative breast cancer; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• SU011248
• Standard chemotherapy

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2011-06-27